Gene editing company Eligo Bioscience has announced a successful $30 million Series B funding round, led by Sanofi Ventures. “We are excited to lead this financing for Eligo and support the company as they move to the clinic,” said Laia Crespo, Partner at Sanofi Ventures. “We are impressed by the unique delivery and editing technologies […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!